Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![OzmosiHealth Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1055982930.png) Ozmosi [@OzmosiHealth](/creator/twitter/OzmosiHealth) on x 2629 followers
Created: 2025-07-09 11:32:37 UTC

$KRYS First patient dosed in Phase 1/2 trial of KB801 for Neurotrophic Keratitis treatment, announces Krystal Biotech.

More Info: $XBI $IBB $XPH $PPH

![](https://pbs.twimg.com/media/GvaaHxpWYAAViYE.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1942909752713134281/c:line.svg)

**Related Topics**
[$pph](/topic/$pph)
[$xph](/topic/$xph)
[$ibb](/topic/$ibb)
[$xbi](/topic/$xbi)
[more info](/topic/more-info)
[$krys](/topic/$krys)

[Post Link](https://x.com/OzmosiHealth/status/1942909752713134281)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

OzmosiHealth Avatar Ozmosi @OzmosiHealth on x 2629 followers Created: 2025-07-09 11:32:37 UTC

$KRYS First patient dosed in Phase 1/2 trial of KB801 for Neurotrophic Keratitis treatment, announces Krystal Biotech.

More Info: $XBI $IBB $XPH $PPH

XXX engagements

Engagements Line Chart

Related Topics $pph $xph $ibb $xbi more info $krys

Post Link

post/tweet::1942909752713134281
/post/tweet::1942909752713134281